RIDDLE&CODE
1.4.2022 10:17:06 CEST | Business Wire | Press release
As of April 1, 2022 , Kai Siefert will take over the managing director position of the blockchain start-up RIDDLE&CODE Energy Solutions GmbH, a joint venture between Wien Energie GmbH, Austria's largest regional energy service provider, and blockchain scale-up RIDDLE&CODE GmbH, also based in Vienna.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220401005045/en/
Kai Siefert has 16 years of professional experience in the energy industry. In his previous position as IT strategist at Wien Energie GmbH, he led a team of software developers and electrical engineers from both joint venture partners to develop blockchain-based digital services and technical solutions for the renewable sector and its distributed energy sources. As a result of this work, the energy tokenisation platform "MyPower" was launched last summer, forming the core product of the young company. Wien Energie GmbH already uses this technology as part of its citizen solar power plant products, where the latest release includes a dynamic incentivisation and remuneration feature.
“Over the past four years, the team has built a digital framework for everyone to participate in decentralised energy markets,” says Siefert. “By using this framework, energy entrepreneurs are able to overcome even the toughest problems, such as asset aggregation and disaggregation, peer-to-peer energy marketing or certificate management. Based on our state-of-the-art tokenisation technology and digital wallets, we provide them with secure, transparent and highly scalable access to value chains of the green economy." As part of his new role, Siefert will focus on the internationalisation of the company and further development of the MyPower platform.
"We have proven the technical and commercial viability of energy tokenization in several "real-market projects" in Vienna. And there is great interest in the solution beyond the Austrian borders. As an immediate success of the whole RIDDLE&CODE Energy Solutions team, I am happy to announce the cooperation with the municipality of Stanz, the Austrian pioneer community of the EU-funded Smart Rural project, which was sealed earlier this week.", says Kai Siefert.
"Kai has done a great job with MyPower, driving strong growth, partnerships, and fantastic product innovation. His track record in the industry speaks for itself as well as his empathy for the challenges enterprises overcome while adopting blockchain technology," said Alexander Koppel, CEO at RIDDLE&CODE GmbH. "We are thrilled to have him as a managing director as we accelerate the next stage of growth."
About RIDDLE&CODE Energy Solutions GmbH
RIDDLE&CODE Energy Solutions GmbH provides blockchain-powered infrastructure that enables resilient, decentralised and fully decarbonized energy markets. With the development of the MyPower platform, the company has demonstrated an effective way for energy players into the machine economy. By tokenizing energy, machines and data, RIDDLE&CODE Energy Solutions GmbH significantly increases the liquidity of distributed assets making them easily accessible to broad investor segments, while their output can be traded and tracked with unprecedented transparency and security.
More information about MyPower: www.riddleandcode.com/energy
View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005045/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom